Sphingolipids, antiplatelet medication in interventional cardiology working group

Our group merges basic, translational and clinical research.

• We investigate the role of sphingolipid sphingosine-1-phosphate (S1P) in cardiovascular diseases using basic and translational science approaches. S1P is a bioactive lipid that plays important roles in immunity, inflammation and cardiovascular biology. We aim to (i) determine the role of S1P in cardiac remodelling, (ii) immunothrombosis and (iii) identify potential therapeutic implications in acute myocardial infarction.

• We conduct translational and clinical studies, investigating efficacy of antiplatelet medication in acute myocardial infarction and interventional cardiology. It is known, that pharmacodynamic response to platelet inhibiting agents like aspirin or clopidogrel varies significantly between individuals. We aim to identify (i) drug-drug interactions causing impaired pharmacodynamic response to antiplatelet medication, (ii) patients at high risk of insufficient pharmacodynamic response to antiplatelet medication and (iii) investigate the optimal antithrombotic regime in interventional cardiology.

• In clinical research, our major interest is in developing/implementing fusion imaging applications in standard of care in interventional cardiology as well as participation in clinical trials in interventional cardiology.